CAZ-AVI, combines a broad-spectrum cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam) will be tested to treat hospitalised patients with serious Gram-negative bacterial infections including complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). The study programme will include five Phase III trials designed to demonstrate that CAZ-AVI is effective for patients with cIAI and cUTI including those with infections that may be resistant to currently available antibiotics.
The decision to advance the drug is based on two Phase II trials and the first showed that the efficacy of CAZ-AVI given with metronidazole in adults was similar to meropenem, an established treatment given to patients with cIAIs. The second study showed that the combo was as effective as imipenem cilastatin, which is used for cUTI patients; the data from both trials showed that CAZ-AVI in general was well tolerated.
Tuesday, October 18, 2011
AZ and Forest put superbug drug into late-stage trials
via pharmatimes.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment